Nelfinavir possibly inhibits the translation and maturation of TCF/Nrf1, leading to the repression of re-synthesis of the proteasome, which can explain the better outcome in clinical trials administering nelfinavir in bortezomib refractory MM [20,76]. Here, NRF1 is linked to Miyoshi myopathy.